FICHIT

Je m'inscris

TRANSGENE

0/5 (0 note(s))
Note donnée : aucune
Paris
135
Immunotherapies for the treatment of cancer and infectious diseases uzing viral vector technology with the goal of killing infected or cancerous cells.
1) TG4010 MUC-1 targeted immunotherapy for the treatment of non-small cell lung cancer (NSCLC) – Phase 2b part of Phase 2b/3 TIME trial evaluating TG4010 with chemotherapy in first-line NSCLC completed and promising data presented; Phase 2 trials in combination with immune checkpoint inhibitors being planned.
2) Pexa-Vec oncolytic immunotherapy about to enter Phase 3 trial in first-line liver cancer with standard of care, sorafenib; several Phase 2 trials in various cancers underway and being planned, including in combination with immune checkpoint inhibitors.
CASTELLI Elisabetta
www.transgene.fr
TNG:FP

Fiche créée le 10/04/2016 par Guillaume   vue 8 fois.